Horizon Therapeutics Ireland Designated Activity Company

• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2023-503904-10-00 Phase III 12 countries DAZODALIBEP
• Neuromyelitis Optica Spectrum Disorder Inebilizumab Study in Children and Adolescents Recruiting
  2023-510007-22-00 Phase II 5 countries
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended
  2023-503923-24-00 Phase III 12 countries DAZODALIBEP
• Inebilizumab efficacy and safety in adults with myasthenia gravis Ended
  2023-510006-40-00 Phase III 5 countries
• A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended
  2023-508290-81-00 Phase III 6 countries
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 Phase II 11 countries VIB1116
• A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. Ended
  2023-509746-35-00 Phase II 7 countries DAXDILIMAB
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 Phase II 9 countries FIPAXALPARANT
• A Study to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis Ended
  2023-509784-24-00 Phase II 6 countries FIPAXALPARANT
• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 Phase II 9 countries FIPAXALPARANT

Showing 1–10 of 10 trials